🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing around the world, with estimates suggesting over 82 million instances annually. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the highly restricted available drugs currently available.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Results and Global Access

As per findings published in a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which involves two antibiotics. The trial included over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced hope. Access to a single-dose, oral treatment of this kind is described as a "game-changer" for managing the epidemic. This is deemed vital to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.